Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards
08 Noviembre 2023 - 7:15AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced it
has received the “Proteomics Company of the Year” award from the
BioTech Breakthrough Awards as part of the program’s 2023 award
recipients for its first of a kind protein sequencing
instrument.
“Since the groundbreaking introduction of Platinum™, Quantum-Si
has swiftly emerged as an industry trailblazer, galvanizing the
scientific community with a pioneering focus on proteomics,” said
Quantum-Si Chief Executive Officer Jeff Hawkins. “Receiving the
coveted Proteomics Company of the Year award in 2023 is a testament
to the extraordinary caliber of our team and the revolutionary
Platinum instrument-an unparalleled milestone in next-generation
protein sequencing™.”
The BioTech Breakthrough Awards program aims to perform the most
comprehensive evaluation of life sciences and biotechnology tools,
services and companies today, with nominations coming in from the
best and brightest biotechnology innovators around the world. This
year, the inclusion of a new awards category in proteomics along
with three subcategories, signals the immense progress the
proteomics industry has made in 2023.
Winners in the various categories are featured online at the
Biotech Breakthrough Awards website. To see the complete list, go
www.biotechbreakthroughawards.com.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; our ongoing
leadership transition; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized PlatinumTM protein
sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108633826/en/
Investors Jeff Keyes, CFO ir@quantum-si.com Media
Katherine Atkinson, SVP Commercial Marketing
media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Quantum Si (NASDAQ:QSI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024